4P7E image
Deposition Date 2014-03-27
Release Date 2014-11-19
Last Version Date 2024-10-09
Entry Detail
PDB ID:
4P7E
Keywords:
TRANSFERASE
Title:
Triazolopyridine compounds as selective JAK1 inhibitors: from hit identification to GLPG0634
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Spodoptera frugiperda
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
2.40 Å
R-Value Free:
0.26
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 41
4P7E validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK2
Gene (Uniprot):JAK2
Chain IDs:A, B
Chain Length:293
Number of Molecules:2
Biological Source:Homo sapiens
UniProt ID:O60674 Pfam ID:PF07714 EC:2.7.10.2
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
PTR A TYR modified residue
Ligand Molecules
2HB
Primary Citation
Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634.
J.Med.Chem. 57 9323 9342 (2014)
PMID: 25369270 DOI: 10.1021/jm501262q

Abstact

Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function. Blockade of the JAK-STAT pathway with a small molecule has been shown to provide therapeutic immunomodulation. Having identified JAK1 as a possible new target for arthritis at Galapagos, the compound library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by 3. Optimization within this chemical series led to identification of GLPG0634 (65, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).

Legend

Protein

Chemical

Disease

Primary Citation of related structures
4P7E